These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9772810)

  • 41. Expenditure and value for money: the challenge of implantable cardioverter defibrillators.
    Boriani G; Biffi M; Martignani C; Diemberger I; Valzania C; Bertini M; Branzi A
    QJM; 2009 May; 102(5):349-56. PubMed ID: 19276209
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outpatient time-specified infusion of fluoropyrimidines by implanted pump is less costly than flat delivery by external pump.
    Lanning RM; Hrushesky WJ
    Prog Clin Biol Res; 1990; 341B():397-409. PubMed ID: 2145587
    [No Abstract]   [Full Text] [Related]  

  • 43. [Policy paper to the cardiac re-sychronization therapy].
    Stellbrink C; Auricchio A; Lemke B; von Scheidt W; Vogt J; Dietz R; Gottwik M; Levenson B; Meinertz T; Osterpey A; Tebbe U; Strasser RH; Werdan K; Arnold G; Behrenbeck D; Fleck E; Trappe HJ;
    Z Kardiol; 2003 Jan; 92(1):96-103. PubMed ID: 12545308
    [No Abstract]   [Full Text] [Related]  

  • 44. Management of arterial injuries caused by laser extraction of indwelling venous pacemaker and defibrillator leads.
    Lawton JS; Moon MR; Curci JA; Rubin BG; Smith TW; Gleva MJ; Damiano RJ
    Pacing Clin Electrophysiol; 2006 Aug; 29(8):917-20. PubMed ID: 16923012
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Should we afford implantable cardioverter defibrillator therapy?
    Camm AJ
    Nat Clin Pract Cardiovasc Med; 2005 Feb; 2(2):59. PubMed ID: 16265354
    [No Abstract]   [Full Text] [Related]  

  • 46. Chapter 10. Current evidence on the cost effectiveness of the implantable cardioverter defibrillator.
    O'Brien BJ; Yee R
    Can J Cardiol; 2000 Jun; 16 Suppl C():45C-7C. PubMed ID: 10887279
    [No Abstract]   [Full Text] [Related]  

  • 47. Introduction of permanent cardiac stimulation/defibrillation leads via the retro-pectoral veins.
    Camous JP; Raybaud F; Lesto I; Benoit PH
    Pacing Clin Electrophysiol; 2005 Apr; 28(4):324-5. PubMed ID: 15826267
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Structure of the Australian system of 'Diagnosis Related Groups' regarding cardiovascular diseases and corresponding cost weights in Germany].
    Wietholt D; Köpfer T; Paul K; Gässler A; Bruch L; Kleber FX
    Z Kardiol; 2003 Aug; 92(8):619-26. PubMed ID: 12955408
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Re-use of devices in cardiology. Proceedings from a Policy Conference at the European Heart House, 5-6 February, 1998.
    Rydén L
    Eur Heart J; 1998 Nov; 19(11):1628-31. PubMed ID: 9857914
    [No Abstract]   [Full Text] [Related]  

  • 50. How should we cost ICD therapy?
    Fox DJ; Davidson NC; Fitzpatrick AP
    Int J Cardiol; 2007 May; 118(1):1-3. PubMed ID: 17258335
    [No Abstract]   [Full Text] [Related]  

  • 51. Viewpoint from Israel.
    Glikson M
    Circulation; 2006 Feb; 113(5):f17-8. PubMed ID: 16461828
    [No Abstract]   [Full Text] [Related]  

  • 52. Grasping the role of technology: a conversation with Ron Dollens. Interview by John K. Iglehart.
    Dollens R
    Health Aff (Millwood); 2005; Suppl Web Exclusives():W5-296-W5-313. PubMed ID: 15975988
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of ICDs.
    Fauchier L; Babuty D
    N Engl J Med; 2006 Jan; 354(2):205-7; author reply 205-7. PubMed ID: 16411302
    [No Abstract]   [Full Text] [Related]  

  • 54. Chapter 3. Cost effectiveness of ICD therapy: a review of published evidence.
    O'Brien BJ
    Can J Cardiol; 2000 Oct; 16(10):1307-12. PubMed ID: 11064306
    [No Abstract]   [Full Text] [Related]  

  • 55. A change of pace.
    Kiser K
    Minn Med; 2006 Nov; 89(11):26-31, 45. PubMed ID: 17153900
    [No Abstract]   [Full Text] [Related]  

  • 56. Disabling the pacemaker: the heart-rending decision every competent patient has a right to make.
    Manganello TD
    Health Care Law Mon; 2000 Jan; ():3-15. PubMed ID: 10788043
    [No Abstract]   [Full Text] [Related]  

  • 57. A cost benefit analysis of different types of pacemaker.
    Fabricius J
    Scand J Thorac Cardiovasc Surg Suppl; 1978; (22):35-7. PubMed ID: 102027
    [No Abstract]   [Full Text] [Related]  

  • 58. Shock treatment. Medicare's coverage of implantable defibrillators adds jolt to electrophysiology specialty, device sales.
    Becker C
    Mod Healthc; 2005 May; 35(19):34, 36. PubMed ID: 15929257
    [No Abstract]   [Full Text] [Related]  

  • 59. Fatal complications of pacemaker and implantable cardioverter-defibrillator implantation: medical malpractice?
    Schulz N; Püschel K; Turk EE
    Interact Cardiovasc Thorac Surg; 2009 Apr; 8(4):444-8. PubMed ID: 19168462
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Insulin pump--25 years old and with a future. It counteracts development of late diabetic complications].
    Adamson U; Lins PE
    Lakartidningen; 2002 Dec; 99(51-52):5168-70. PubMed ID: 12572311
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.